9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on patients with rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease, as well as for undisclosed rare diseases and/or unmet needs. It is Initiating their Phase 2 trial of vurolenatide marks an important milestone for patients and families impacted by the debilitating effects of short bowel syndrome, including chronic diarrhea.
It has just been added to Russell 2000(R) and 3000(R) Indexes.